



PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 89194

Title: Anti-EGFR antibody monotherapy for colorectal cancer with severe hyperbilirubinemia: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05848404

Position: Peer Reviewer

Academic degree: MD

Professional title: Chief Doctor, Dean, Professor, Surgeon

Reviewer's Country/Territory: China

Author's Country/Territory: Japan

Manuscript submission date: 2023-10-25

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-10-28 07:34

Reviewer performed review: 2023-10-30 03:09

Review time: 1 Day and 19 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This case report describes a patient in his 50s who was treated for sigmoid cancer with multiple liver metastases. Due to the combination of hyperbilirubinemia and failure of biliary drainage, the patient was unable to receive conventional chemotherapy regimens. In the absence of RAS mutations, the authors developed a regimen of panizumab monotherapy for this patient. The result shows that anti-EGFR monotherapy is safe and effective in the treatment of hyperbilirubinemia caused by colon cancer complicated with liver metastasis.



PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 89194

Title: Anti-EGFR antibody monotherapy for colorectal cancer with severe hyperbilirubinemia: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05222067

Position: Peer Reviewer

Academic degree: MD

Professional title: Associate Chief Physician, Surgeon

Reviewer's Country/Territory: China

Author's Country/Territory: Japan

Manuscript submission date: 2023-10-25

Reviewer chosen by: Yu-Lu Chen

Reviewer accepted review: 2023-11-20 02:50

Reviewer performed review: 2023-11-20 06:12

Review time: 3 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

‘Anti-EGFR antibody monotherapy for colorectal cancer with severe hyperbilirubinemia: A case report and review of the literature’ introduced a potential useful therapeutic method for CRC patient with severe hyperbilirubinemia. The topic is very interesting. The author introduced the information of the patient clearly. The suggestions are followed. 1. Reduce the Core Tip section. Take-home message. 2. Present HE staining figures for the ‘FURTHER DIAGNOSTIC WORK-UP’ section. 3. Change Figure 2 as black lines rather than gray ones. 4. In Table 1, it is recommended to list the outcome or results of such reports.